NEUTRALIZING ANTIBODIES AND COVID-19

Attacking the coronavirus will require a diverse set of approaches, including both vaccines and treatments, such as antibodies

Developing any approach against COVID-19 involves assessing key factors:

Viral exposure
A vaccine will not help an already-infected patient



Stage of disease
When to apply the medicine to prevent the infection or treat the disease

Escape mutations
Potential resistance to a vaccine or treatment



At-risk populations
Factors linked to worse outcomes (e.g., age, concurrent diseases)

Neutralizing Antibodies as Potential Treatments

Identified and characterized using various methods, including from the **blood of COVID-19 survivors**, neutralizing antibodies target the viral spike protein that SARS-CoV-2 uses to gain entry into host cells. Neutralizing antibodies, therefore, are **specifically designed to treat COVID-19**.



Key Characteristics of Neutralizing Antibodies

Potential utility to be **applied either as a single antibody or a combination** based on potential resistance

Wide range of **potential uses as treatment or prevention** (PEP, PREP)



Next Steps

Lilly has **a unique set of antibodies** with an integrated strategy to address COVID-19. The safety and efficacy of these antibodies is being **tested in carefully controlled randomized clinical trials.** And depending on those results, Lilly is committed to working with regulators to bring potential therapies to patients as quickly and safely as possible.

PEP: Post-Exposure Prophylaxis, PrEP: Pre-Exposure Prophylaxis
* As demonstrated by early phase modeling (computational, cell culture, animal models)